Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imugene ( (AU:IMU) ) just unveiled an update.
Imugene Limited has released a capital raising presentation outlining plans for a two-tranche, non-underwritten placement and a share purchase plan of new fully paid ordinary shares with attaching options. The offer is being conducted with the support of three joint lead managers, Barrenjoey Markets, E&P Capital and Bell Potter Securities, who will act solely for the company in arranging the transaction.
The documentation emphasises that the offer is subject to extensive legal and regulatory constraints, including international offer restrictions, particularly in the United States. Disclaimers stress that the materials do not constitute a prospectus or investment advice, detail the absence of underwriting, and highlight that neither Imugene nor the joint lead managers accept liability for reliance on the presentation, underscoring the risk framework around the capital raising.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.21 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an Australia-based biotechnology company focused on innovation in cancer treatment. Listed on the ASX under the ticker IMU, the company develops immuno-oncology therapies aimed at improving outcomes for cancer patients across global markets.
Average Trading Volume: 1,405,648
Technical Sentiment Signal: Sell
Current Market Cap: A$73.95M
For a thorough assessment of IMU stock, go to TipRanks’ Stock Analysis page.